Search

Displaying results 6981 - 6990 of 10000 in total
  1. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).

    Categories: Complex Mixtures
  2. Drug

    Cobolimab

    go.drugbank.com/drugs/DB16372
    Investigational

    Cobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).

  3. Drug

    Rulonilimab

    go.drugbank.com/drugs/DB18922
    Investigational

    Rulonilimab is under investigation in clinical trial NCT05408221 (The Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma).

  4. Drug

    Fallypride

    go.drugbank.com/drugs/DB15167
    Investigational

    Fallypride is under investigation in clinical trial NCT02310360 (Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans).

  5. Drug

    Ivuxolimab

    go.drugbank.com/drugs/DB16208
    Investigational

    Ivuxolimab is under investigation in clinical trial NCT02554812 (A Study of Avelumab in Combination With Other Cancer Immunotherapies in Advanced Malignancies (JAVELIN Medley)).

  6. Drug

    Lactoferrin

    go.drugbank.com/drugs/DB16555
    Investigational

    Lactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis).

  7. Drug

    Candoxatrilat

    go.drugbank.com/drugs/DB11623
    Experimental

    A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure.

  8. Drug

    TAS-102

    go.drugbank.com/drugs/DB08937
    Investigational

    TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer.

  9. Drug

    Eptifibatide

    go.drugbank.com/drugs/DB00063
    ApprovedInvestigational

    Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide th...

  10. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    This recombinant BCG, VPM1002, has been created in response and investigated for preventing pulmonary TB in newborns and TB recurrence in adults through post-exposure immunization. … Because Hly is only active at an acidic pH, similar to listeriolysin O, the deletion of urease C was also beneficial for Hly to have optimal bioactivity in the phagosome.

    Categories: Complex Mixtures